The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review. The European Medicines Agency (EMA) in late January said the European Commission had requested a review of additional safety information for the drug,

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status.